NO2005014I2 - En kombinasjon omfattende abakavir, fortrinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortrinnsvis i form av et fysiologisk funksjonelt salt - Google Patents

En kombinasjon omfattende abakavir, fortrinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortrinnsvis i form av et fysiologisk funksjonelt salt

Info

Publication number
NO2005014I2
NO2005014I2 NO2005014C NO2005014C NO2005014I2 NO 2005014 I2 NO2005014 I2 NO 2005014I2 NO 2005014 C NO2005014 C NO 2005014C NO 2005014 C NO2005014 C NO 2005014C NO 2005014 I2 NO2005014 I2 NO 2005014I2
Authority
NO
Norway
Prior art keywords
physiologically functional
functional salt
abacavir
lamivudine
combination
Prior art date
Application number
NO2005014C
Other languages
English (en)
Other versions
NO2005014I1 (no
Original Assignee
Viiv Healthcare Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2005014(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Application filed by Viiv Healthcare Uk Ltd filed Critical Viiv Healthcare Uk Ltd
Publication of NO2005014I1 publication Critical patent/NO2005014I1/no
Publication of NO2005014I2 publication Critical patent/NO2005014I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
NO2005014C 1995-03-30 2005-05-24 En kombinasjon omfattende abakavir, fortrinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortrinnsvis i form av et fysiologisk funksjonelt salt NO2005014I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
NO2005014I1 NO2005014I1 (no) 2005-06-06
NO2005014I2 true NO2005014I2 (no) 2008-02-11

Family

ID=26306774

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19974510A NO313787B1 (no) 1995-03-30 1997-09-29 Synergistiske blandinger av 1592U89 og 3TC og eventuelt zidovudin, farmasöytiske formuleringer og produkter inneholdendedem, samt anvendelse av dem
NO2005014C NO2005014I2 (no) 1995-03-30 2005-05-24 En kombinasjon omfattende abakavir, fortrinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortrinnsvis i form av et fysiologisk funksjonelt salt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19974510A NO313787B1 (no) 1995-03-30 1997-09-29 Synergistiske blandinger av 1592U89 og 3TC og eventuelt zidovudin, farmasöytiske formuleringer og produkter inneholdendedem, samt anvendelse av dem

Country Status (35)

Country Link
US (1) US6417191B1 (no)
EP (1) EP0817637B1 (no)
JP (1) JP2954357B2 (no)
KR (1) KR100542536B1 (no)
CN (1) CN1103593C (no)
AP (1) AP652A (no)
AT (1) ATE220551T1 (no)
AU (1) AU715213B2 (no)
BR (3) BRPI9607851B8 (no)
CA (1) CA2216634C (no)
CZ (1) CZ295940B6 (no)
DE (3) DE69622386T2 (no)
DK (1) DK0817637T3 (no)
EA (1) EA000626B3 (no)
EE (1) EE04047B1 (no)
ES (1) ES2179193T3 (no)
FR (1) FR05C0022I2 (no)
GE (1) GEP20022647B (no)
HU (1) HU224010B1 (no)
IL (1) IL117727A (no)
LU (1) LU91171I2 (no)
MX (1) MX9707316A (no)
MY (1) MY115461A (no)
NL (1) NL300195I2 (no)
NO (2) NO313787B1 (no)
NZ (1) NZ306419A (no)
OA (1) OA10616A (no)
PL (1) PL187085B1 (no)
PT (1) PT817637E (no)
RO (1) RO117995B1 (no)
SI (1) SI0817637T1 (no)
SK (1) SK283825B6 (no)
TR (1) TR199701074T1 (no)
UA (1) UA60293C2 (no)
WO (1) WO1996030025A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
JP5467870B2 (ja) * 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
EP3347340A4 (en) 2015-09-08 2019-01-23 Monash University LYMPHENLEITUNGSPRODRUGS
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
AU2021217172A1 (en) 2020-02-05 2022-09-22 Monash University Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DE69206876T3 (de) 1991-05-16 2004-08-12 Glaxo Group Ltd., Greenford Nukleosidanalogen enthaltende Antiviren-Zubereitungen
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
ATE220551T1 (de) 2002-08-15
CN1103593C (zh) 2003-03-26
JP2954357B2 (ja) 1999-09-27
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
CA2216634C (en) 2004-07-20
CN1185110A (zh) 1998-06-17
AP9701089A0 (en) 1997-10-31
IL117727A0 (en) 1996-07-23
GEP20022647B (en) 2002-03-25
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
IL117727A (en) 1999-11-30
MX9707316A (es) 1997-11-29
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
JPH10511682A (ja) 1998-11-10
HUP9801571A3 (en) 2001-04-28
EP0817637B1 (en) 2002-07-17
BRPI9612992B1 (pt) 2020-08-04
EP0817637A1 (en) 1998-01-14
DE69622386T2 (de) 2003-02-13
EA000626B3 (ru) 2016-04-29
NO313787B1 (no) 2002-12-02
FR05C0022I2 (no) 2005-10-21
SI0817637T1 (en) 2002-10-31
EA199700203A1 (ru) 1998-02-26
AU5497296A (en) 1996-10-16
OA10616A (en) 2001-03-15
AP652A (en) 1998-06-19
KR100542536B1 (ko) 2006-03-23
DE122005000029I1 (de) 2005-10-06
PL187085B1 (pl) 2004-05-31
BR9607851A (pt) 1998-07-21
BR9607851B1 (pt) 2009-01-13
DK0817637T3 (da) 2002-11-11
CZ295940B6 (cs) 2005-12-14
EA000626B1 (ru) 1999-12-29
UA60293C2 (uk) 2003-10-15
HU224010B1 (hu) 2005-04-28
ES2179193T3 (es) 2003-01-16
NO2005014I1 (no) 2005-06-06
FR05C0022I1 (no) 2005-06-10
MY115461A (en) 2003-06-30
LU91171I9 (no) 2018-12-28
LU91171I2 (fr) 2005-07-04
NO974510D0 (no) 1997-09-29
BRPI9607851B8 (pt) 2019-11-05
KR19980703420A (ko) 1998-11-05
AU715213B2 (en) 2000-01-20
CA2216634A1 (en) 1996-10-03
CZ309097A3 (cs) 1998-05-13
RO117995B1 (ro) 2002-12-30
PL322532A1 (en) 1998-02-02
US6417191B1 (en) 2002-07-09
HK1009401A1 (en) 1999-09-10
SK129597A3 (en) 1998-07-08
DE122005000029I2 (de) 2006-04-27
HUP9801571A2 (hu) 1999-01-28
NO974510L (no) 1997-09-29
EE04047B1 (et) 2003-06-16
EE9700240A (et) 1998-04-15
NL300195I2 (nl) 2005-11-01
DE69622386D1 (de) 2002-08-22

Similar Documents

Publication Publication Date Title
NO2005014I1 (no) En kombinasjon omfattende abakavir, fortinnsvis i form av et fysiologisk funksjonelt salt og lamivudin, fortinnsvis i form av et fysiologisk funksjonet salt
DE69531399D1 (de) Kunstherz
NO2001002I1 (no) Lamivudin, eventuelt i form av et farmasøytisk godtgbart salt
DE69529598D1 (de) Arzneimittelenthaltende Manschette
DE69509743D1 (de) Bauspielzeug
LT97145A (lt) Pirazol-4-il-benzoilo dariniai ir herbicidinė priemonė
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
NO965023L (no) Maltitolblanding og fremstilling derav
NO972103L (no) Eleutherobin og analoger av denne
DE69615215D1 (de) Trittbrett
DE69620753D1 (de) Eiswiderstandsfähiger gefrorener Teig
FI964456L (fi) Makuainepohja
KR970004327U (ko) 종합신체단련기구
KR970000080A (ko) 김양념 조미액 및 그 제조방법
KR960028373U (ko) 놀이용 골프 세트
BR7502451U (pt) Brinquedo
KR970020677U (ko) 보석을 이용한 건강베개
KR950013372U (ko) 방향 장식구
BR9505341A (pt) Jogo
KR970000305U (ko) 인형옷걸이
KR960026772U (ko) 장식용 인형
KR970016315U (ko) 오뚜기 완구
KR970004089U (ko) 평대형 쇼케이스
DK0797468T3 (da) Lege- og sportsredskab
BR7500032U (pt) Jogo ligue letras